世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
ヘモグロビン異常症市場：タイプ別（サラセミア、鎌状赤血球症、その他）、治療法別（モノクローナル抗体薬、ACE阻害剤、ヒドロキシ尿素、その他）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局）。世界の機会分析および産業予測、2021-2031年Hemoglobinopathies Market By Type (Thalassemia, Sickle Cell Disease, Others), By Therapy (Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea, Others), By Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031 ヘモグロビン異常症は、主に赤血球（RBC）が侵される血液疾患の総称です。ヘモグロビン分子の異常産生や構造変化により、ヘモグロビン異常症が引き起こされます。ヘモグロビン異常症は大きく分けて、構造異常ヘモ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーヘモグロビン異常症は、主に赤血球（RBC）が侵される血液疾患の総称です。ヘモグロビン分子の異常産生や構造変化により、ヘモグロビン異常症が引き起こされます。ヘモグロビン異常症は大きく分けて、構造異常ヘモグロビン変異型とサラセミアに分類されます。構造異常ヘモグロビン変異体はヘモグロビン遺伝子構造の変異によって、サラセミアはヘモグロビン分子の産生異常または産生不足によって起こります。多くのヘモグロビン異常症は、現在、いくつかの医薬品が承認され、また、いくつかの医薬品が開発段階にあります。鎌状赤血球症（SCD）およびサラセミアの有病率の増加は、市場成長の原動力になると予想されます。世界のヘモグロビン症市場の成長の主な要因は、低開発国および発展途上国におけるヘモグロビン症の有病率の増加です。また、認知度の低さや診断率の低さも、ヘモグロビン異常症の有病率を高める主な要因となっています。さらに、代替治療法の欠如、治療法の入手不可能性、診断率の低さが、予測期間中の世界のヘモグロビンオパチー市場の成長を抑制する要因となっています。ヘモグロビン異常症市場は、ベータサラセミアと鎌状赤血球症の治療法の登場により成長すると予測されます。遺伝子補正された幹細胞の移植に基づく治療法では、レンチウイルスベクターがベータグロビン鎖を移植し、ベータグロビン遺伝子座によって転写が制御されます。例えば、幹細胞の量と質の不足、遺伝子発現の複雑さ、治療費の高さなど、市場の成長を制限するさまざまな要因があります。 ヘモグロビン異常症市場は、疾患タイプ、治療法の種類、流通チャネル、地域に基づいてセグメント化されています。疾患タイプ別に見ると、市場はサラセミア、鎌状赤血球症、その他に分類されます。その他はさらに、ヘモグロビン（Hb）変異体、βサラセミア、αサラセミア、ポルフィリン症に分類されます。治療法の種類別に見ると、モノクローナル抗体薬、アンジオテンシン変換酵素（ACE）阻害剤、幹細胞移植、ヒドロキシ尿素、その他に分類されます。さらに、その他は、遺伝子治療、鉄キレート療法、輸血、骨髄移植に分類されます。流通経路別では、病院薬局、オンラインプロバイダー、ドラッグストアや小売薬局に分類されます。 地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。世界のヘモグロビン異常症市場で事業を展開する主な主要企業は、Abbott Laboratories、Alnylam Pharmaceuticals、Biogen Idec、Bluebird、Inc、Bristol Myers Squibb Company、Canthera Discovery Ltd、Danaher、Emmacus Life Science Inc、F. Hoffman-La Roche Ag、Gamida Cell Ltd、Global blood therapeutics、Merck & Co., Novartis AG, Pfizer, Inc、Prolong Pharmaceuticals, LLC、Sangamo TherapeuticsおよびSanofiなどです。 ステークホルダーにとっての主なメリット ●本レポートは、2021年から2031年までのヘモグロビン異常症市場分析の市場セグメント、現在のトレンド、予測、ダイナミクスを定量的に分析し、ヘモグロビン異常症市場の優勢な機会を特定します。 ●市場調査は、主要な推進要因、抑制要因、機会に関連する情報とともに提供されます。 ポーターのファイブフォース分析により、買い手と供給者の潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、供給者と買い手のネットワークを強化できるようにします。 ヘモグロビン異常症市場のセグメンテーションを詳細に分析することで、市場機会を決定することができます。 ヘモグロビン異常症市場の詳細な分析は、市場機会を決定するのに役立ちます。 市場プレイヤーのポジショニングにより、ベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。 地域別および世界別のヘモグロビン異常症市場動向、キープレイヤー、市場セグメント、応用分野、市場成長戦略などの分析が含まれています。 主な市場セグメント タイプ別 サラセミア 鎌状赤血球症 その他 治療法別 モノクローナル抗体薬 ACE阻害剤 ヒドロキシ尿素 ヒドロキシ尿素 ● その他 販売チャネル別 病院薬局 オンラインプロバイダー ドラッグストア・小売店 地域別 北米 米国 カナダ メキシコ 欧州 ドイツ フランス イギリス イタリア スペイン その他のヨーロッパ アジア太平洋地域 日本 中国 オーストラリア インド 韓国 その他のアジア太平洋地域 LAMEA ブラジル サウジアラビア 南アフリカ LAMEAの残りの地域 主な市場関係者 アボット・ラボラトリーズ アルニラム・ファーマシューティカルズ株式会社 バイオジェンIDC ブルーバード ブリストル・マイヤーズ スクイブ ダナハーコーポレーション エマウス・ライフサイエンス・インク グローバル・ブラッド・セラピューティック社 ○ Merck & Co.Inc. ノバルティスAG ファイザー プロロング・ファーマシューティカルズ Sangamo Therapeutics, Inc. サノフィ キャンサー・セラピューティクス CRC Pty Ltd ガミダセル社 目次CHAPTER 1:INTRODUCTION1.1.Report description 1.2.Key market segments 1.3.Key benefits to the stakeholders 1.4.Research Methodology 1.4.1.Secondary research 1.4.2.Primary research 1.4.3.Analyst tools and models CHAPTER 2:EXECUTIVE SUMMARY 2.1.Key findings of the study 2.2.CXO Perspective CHAPTER 3:MARKET OVERVIEW 3.1.Market definition and scope 3.2.Key findings 3.2.1.Top investment pockets 3.3.Porter’s five forces analysis 3.4.Top player positioning 3.5.Market dynamics 3.5.1.Drivers 3.5.2.Restraints 3.5.3.Opportunities 3.6.COVID-19 Impact Analysis on the market CHAPTER 4: HEMOGLOBINOPATHIES MARKET, BY TYPE 4.1 Overview 4.1.1 Market size and forecast 4.2 Thalassemia 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Sickle Cell Disease 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Others 4.4.1 Key market trends, growth factors and opportunities 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country CHAPTER 5: HEMOGLOBINOPATHIES MARKET, BY THERAPY 5.1 Overview 5.1.1 Market size and forecast 5.2 Monoclonal Antibody Medication 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 ACE inhibitors 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Hydroxyurea 5.4.1 Key market trends, growth factors and opportunities 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Others 5.5.1 Key market trends, growth factors and opportunities 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL 6.1 Overview 6.1.1 Market size and forecast 6.2 Hospital Pharmacy 6.2.1 Key market trends, growth factors and opportunities 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Online Providers 6.3.1 Key market trends, growth factors and opportunities 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country 6.4 Drug Stores and Retail Pharmacy 6.4.1 Key market trends, growth factors and opportunities 6.4.2 Market size and forecast, by region 6.4.3 Market analysis by country CHAPTER 7: HEMOGLOBINOPATHIES MARKET, BY REGION 7.1 Overview 7.1.1 Market size and forecast 7.2 North America 7.2.1 Key trends and opportunities 7.2.2 North America Market size and forecast, by Type 7.2.3 North America Market size and forecast, by Therapy 7.2.4 North America Market size and forecast, by Distribution Channel 7.2.5 North America Market size and forecast, by country 7.2.5.1 U.S. 7.2.5.1.1 Market size and forecast, by Type 7.2.5.1.2 Market size and forecast, by Therapy 7.2.5.1.3 Market size and forecast, by Distribution Channel 7.2.5.2 Canada 7.2.5.2.1 Market size and forecast, by Type 7.2.5.2.2 Market size and forecast, by Therapy 7.2.5.2.3 Market size and forecast, by Distribution Channel 7.2.5.3 Mexico 7.2.5.3.1 Market size and forecast, by Type 7.2.5.3.2 Market size and forecast, by Therapy 7.2.5.3.3 Market size and forecast, by Distribution Channel 7.3 Europe 7.3.1 Key trends and opportunities 7.3.2 Europe Market size and forecast, by Type 7.3.3 Europe Market size and forecast, by Therapy 7.3.4 Europe Market size and forecast, by Distribution Channel 7.3.5 Europe Market size and forecast, by country 7.3.5.1 Germany 7.3.5.1.1 Market size and forecast, by Type 7.3.5.1.2 Market size and forecast, by Therapy 7.3.5.1.3 Market size and forecast, by Distribution Channel 7.3.5.2 France 7.3.5.2.1 Market size and forecast, by Type 7.3.5.2.2 Market size and forecast, by Therapy 7.3.5.2.3 Market size and forecast, by Distribution Channel 7.3.5.3 UK 7.3.5.3.1 Market size and forecast, by Type 7.3.5.3.2 Market size and forecast, by Therapy 7.3.5.3.3 Market size and forecast, by Distribution Channel 7.3.5.4 Italy 7.3.5.4.1 Market size and forecast, by Type 7.3.5.4.2 Market size and forecast, by Therapy 7.3.5.4.3 Market size and forecast, by Distribution Channel 7.3.5.5 Spain 7.3.5.5.1 Market size and forecast, by Type 7.3.5.5.2 Market size and forecast, by Therapy 7.3.5.5.3 Market size and forecast, by Distribution Channel 7.3.5.6 Rest of Europe 7.3.5.6.1 Market size and forecast, by Type 7.3.5.6.2 Market size and forecast, by Therapy 7.3.5.6.3 Market size and forecast, by Distribution Channel 7.4 Asia-Pacific 7.4.1 Key trends and opportunities 7.4.2 Asia-Pacific Market size and forecast, by Type 7.4.3 Asia-Pacific Market size and forecast, by Therapy 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel 7.4.5 Asia-Pacific Market size and forecast, by country 7.4.5.1 Japan 7.4.5.1.1 Market size and forecast, by Type 7.4.5.1.2 Market size and forecast, by Therapy 7.4.5.1.3 Market size and forecast, by Distribution Channel 7.4.5.2 China 7.4.5.2.1 Market size and forecast, by Type 7.4.5.2.2 Market size and forecast, by Therapy 7.4.5.2.3 Market size and forecast, by Distribution Channel 7.4.5.3 Australia 7.4.5.3.1 Market size and forecast, by Type 7.4.5.3.2 Market size and forecast, by Therapy 7.4.5.3.3 Market size and forecast, by Distribution Channel 7.4.5.4 India 7.4.5.4.1 Market size and forecast, by Type 7.4.5.4.2 Market size and forecast, by Therapy 7.4.5.4.3 Market size and forecast, by Distribution Channel 7.4.5.5 South Korea 7.4.5.5.1 Market size and forecast, by Type 7.4.5.5.2 Market size and forecast, by Therapy 7.4.5.5.3 Market size and forecast, by Distribution Channel 7.4.5.6 Rest of Asia-Pacific 7.4.5.6.1 Market size and forecast, by Type 7.4.5.6.2 Market size and forecast, by Therapy 7.4.5.6.3 Market size and forecast, by Distribution Channel 7.5 LAMEA 7.5.1 Key trends and opportunities 7.5.2 LAMEA Market size and forecast, by Type 7.5.3 LAMEA Market size and forecast, by Therapy 7.5.4 LAMEA Market size and forecast, by Distribution Channel 7.5.5 LAMEA Market size and forecast, by country 7.5.5.1 Brazil 7.5.5.1.1 Market size and forecast, by Type 7.5.5.1.2 Market size and forecast, by Therapy 7.5.5.1.3 Market size and forecast, by Distribution Channel 7.5.5.2 Saudi Arabia 7.5.5.2.1 Market size and forecast, by Type 7.5.5.2.2 Market size and forecast, by Therapy 7.5.5.2.3 Market size and forecast, by Distribution Channel 7.5.5.3 South Africa 7.5.5.3.1 Market size and forecast, by Type 7.5.5.3.2 Market size and forecast, by Therapy 7.5.5.3.3 Market size and forecast, by Distribution Channel 7.5.5.4 Rest of LAMEA 7.5.5.4.1 Market size and forecast, by Type 7.5.5.4.2 Market size and forecast, by Therapy 7.5.5.4.3 Market size and forecast, by Distribution Channel CHAPTER 8: COMPANY LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Key developments CHAPTER 9: COMPANY PROFILES 9.1 Abbott Laboratories 9.1.1 Company overview 9.1.2 Company snapshot 9.1.3 Operating business segments 9.1.4 Product portfolio 9.1.5 Business performance 9.1.6 Key strategic moves and developments 9.2 Alnylam Pharmaceuticals, Inc. 9.2.1 Company overview 9.2.2 Company snapshot 9.2.3 Operating business segments 9.2.4 Product portfolio 9.2.5 Business performance 9.2.6 Key strategic moves and developments 9.3 Biogen idc 9.3.1 Company overview 9.3.2 Company snapshot 9.3.3 Operating business segments 9.3.4 Product portfolio 9.3.5 Business performance 9.3.6 Key strategic moves and developments 9.4 Bluebird, Inc. 9.4.1 Company overview 9.4.2 Company snapshot 9.4.3 Operating business segments 9.4.4 Product portfolio 9.4.5 Business performance 9.4.6 Key strategic moves and developments 9.5 Bristol Myers Squibb 9.5.1 Company overview 9.5.2 Company snapshot 9.5.3 Operating business segments 9.5.4 Product portfolio 9.5.5 Business performance 9.5.6 Key strategic moves and developments 9.6 Danaher Corporation 9.6.1 Company overview 9.6.2 Company snapshot 9.6.3 Operating business segments 9.6.4 Product portfolio 9.6.5 Business performance 9.6.6 Key strategic moves and developments 9.7 Emmaus Life Sciences, Inc. 9.7.1 Company overview 9.7.2 Company snapshot 9.7.3 Operating business segments 9.7.4 Product portfolio 9.7.5 Business performance 9.7.6 Key strategic moves and developments 9.8 Global Blood Therapeutics, Inc. 9.8.1 Company overview 9.8.2 Company snapshot 9.8.3 Operating business segments 9.8.4 Product portfolio 9.8.5 Business performance 9.8.6 Key strategic moves and developments 9.9 Merck & Co. Inc. 9.9.1 Company overview 9.9.2 Company snapshot 9.9.3 Operating business segments 9.9.4 Product portfolio 9.9.5 Business performance 9.9.6 Key strategic moves and developments 9.10 Novartis AG 9.10.1 Company overview 9.10.2 Company snapshot 9.10.3 Operating business segments 9.10.4 Product portfolio 9.10.5 Business performance 9.10.6 Key strategic moves and developments 9.11 Pfizer 9.11.1 Company overview 9.11.2 Company snapshot 9.11.3 Operating business segments 9.11.4 Product portfolio 9.11.5 Business performance 9.11.6 Key strategic moves and developments 9.12 Prolong Pharmaceuticals 9.12.1 Company overview 9.12.2 Company snapshot 9.12.3 Operating business segments 9.12.4 Product portfolio 9.12.5 Business performance 9.12.6 Key strategic moves and developments 9.13 Sangamo Therapeutics, Inc. 9.13.1 Company overview 9.13.2 Company snapshot 9.13.3 Operating business segments 9.13.4 Product portfolio 9.13.5 Business performance 9.13.6 Key strategic moves and developments 9.14 Sanofi 9.14.1 Company overview 9.14.2 Company snapshot 9.14.3 Operating business segments 9.14.4 Product portfolio 9.14.5 Business performance 9.14.6 Key strategic moves and developments 9.15 Cancer Therapeutics CRC Pty Ltd 9.15.1 Company overview 9.15.2 Company snapshot 9.15.3 Operating business segments 9.15.4 Product portfolio 9.15.5 Business performance 9.15.6 Key strategic moves and developments 9.16 Gamida-Cell Ltd. 9.16.1 Company overview 9.16.2 Company snapshot 9.16.3 Operating business segments 9.16.4 Product portfolio 9.16.5 Business performance 9.16.6 Key strategic moves and developments
SummaryHemoglobinopathy is a collective term used for the blood disorder that primarily affects the red blood cells (RBCs). The abnormal production or structural change in the hemoglobin molecule causes hemoglobinopathies. Majorly, hemoglobinopathies are divided into two groups, namely abnormal structural hemoglobin variant and thalassemia. The abnormal structural hemoglobin variants are caused by mutations in the hemoglobin gene structure and thalassemia is occurred by abnormal or underproduction of hemoglobin molecules. Many hemoglobinopathies currently have some approved drugs in the market and some drugs are in development stages. Table of ContentsCHAPTER 1:INTRODUCTION1.1.Report description 1.2.Key market segments 1.3.Key benefits to the stakeholders 1.4.Research Methodology 1.4.1.Secondary research 1.4.2.Primary research 1.4.3.Analyst tools and models CHAPTER 2:EXECUTIVE SUMMARY 2.1.Key findings of the study 2.2.CXO Perspective CHAPTER 3:MARKET OVERVIEW 3.1.Market definition and scope 3.2.Key findings 3.2.1.Top investment pockets 3.3.Porter’s five forces analysis 3.4.Top player positioning 3.5.Market dynamics 3.5.1.Drivers 3.5.2.Restraints 3.5.3.Opportunities 3.6.COVID-19 Impact Analysis on the market CHAPTER 4: HEMOGLOBINOPATHIES MARKET, BY TYPE 4.1 Overview 4.1.1 Market size and forecast 4.2 Thalassemia 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Sickle Cell Disease 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Others 4.4.1 Key market trends, growth factors and opportunities 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country CHAPTER 5: HEMOGLOBINOPATHIES MARKET, BY THERAPY 5.1 Overview 5.1.1 Market size and forecast 5.2 Monoclonal Antibody Medication 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 ACE inhibitors 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Hydroxyurea 5.4.1 Key market trends, growth factors and opportunities 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Others 5.5.1 Key market trends, growth factors and opportunities 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL 6.1 Overview 6.1.1 Market size and forecast 6.2 Hospital Pharmacy 6.2.1 Key market trends, growth factors and opportunities 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Online Providers 6.3.1 Key market trends, growth factors and opportunities 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country 6.4 Drug Stores and Retail Pharmacy 6.4.1 Key market trends, growth factors and opportunities 6.4.2 Market size and forecast, by region 6.4.3 Market analysis by country CHAPTER 7: HEMOGLOBINOPATHIES MARKET, BY REGION 7.1 Overview 7.1.1 Market size and forecast 7.2 North America 7.2.1 Key trends and opportunities 7.2.2 North America Market size and forecast, by Type 7.2.3 North America Market size and forecast, by Therapy 7.2.4 North America Market size and forecast, by Distribution Channel 7.2.5 North America Market size and forecast, by country 7.2.5.1 U.S. 7.2.5.1.1 Market size and forecast, by Type 7.2.5.1.2 Market size and forecast, by Therapy 7.2.5.1.3 Market size and forecast, by Distribution Channel 7.2.5.2 Canada 7.2.5.2.1 Market size and forecast, by Type 7.2.5.2.2 Market size and forecast, by Therapy 7.2.5.2.3 Market size and forecast, by Distribution Channel 7.2.5.3 Mexico 7.2.5.3.1 Market size and forecast, by Type 7.2.5.3.2 Market size and forecast, by Therapy 7.2.5.3.3 Market size and forecast, by Distribution Channel 7.3 Europe 7.3.1 Key trends and opportunities 7.3.2 Europe Market size and forecast, by Type 7.3.3 Europe Market size and forecast, by Therapy 7.3.4 Europe Market size and forecast, by Distribution Channel 7.3.5 Europe Market size and forecast, by country 7.3.5.1 Germany 7.3.5.1.1 Market size and forecast, by Type 7.3.5.1.2 Market size and forecast, by Therapy 7.3.5.1.3 Market size and forecast, by Distribution Channel 7.3.5.2 France 7.3.5.2.1 Market size and forecast, by Type 7.3.5.2.2 Market size and forecast, by Therapy 7.3.5.2.3 Market size and forecast, by Distribution Channel 7.3.5.3 UK 7.3.5.3.1 Market size and forecast, by Type 7.3.5.3.2 Market size and forecast, by Therapy 7.3.5.3.3 Market size and forecast, by Distribution Channel 7.3.5.4 Italy 7.3.5.4.1 Market size and forecast, by Type 7.3.5.4.2 Market size and forecast, by Therapy 7.3.5.4.3 Market size and forecast, by Distribution Channel 7.3.5.5 Spain 7.3.5.5.1 Market size and forecast, by Type 7.3.5.5.2 Market size and forecast, by Therapy 7.3.5.5.3 Market size and forecast, by Distribution Channel 7.3.5.6 Rest of Europe 7.3.5.6.1 Market size and forecast, by Type 7.3.5.6.2 Market size and forecast, by Therapy 7.3.5.6.3 Market size and forecast, by Distribution Channel 7.4 Asia-Pacific 7.4.1 Key trends and opportunities 7.4.2 Asia-Pacific Market size and forecast, by Type 7.4.3 Asia-Pacific Market size and forecast, by Therapy 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel 7.4.5 Asia-Pacific Market size and forecast, by country 7.4.5.1 Japan 7.4.5.1.1 Market size and forecast, by Type 7.4.5.1.2 Market size and forecast, by Therapy 7.4.5.1.3 Market size and forecast, by Distribution Channel 7.4.5.2 China 7.4.5.2.1 Market size and forecast, by Type 7.4.5.2.2 Market size and forecast, by Therapy 7.4.5.2.3 Market size and forecast, by Distribution Channel 7.4.5.3 Australia 7.4.5.3.1 Market size and forecast, by Type 7.4.5.3.2 Market size and forecast, by Therapy 7.4.5.3.3 Market size and forecast, by Distribution Channel 7.4.5.4 India 7.4.5.4.1 Market size and forecast, by Type 7.4.5.4.2 Market size and forecast, by Therapy 7.4.5.4.3 Market size and forecast, by Distribution Channel 7.4.5.5 South Korea 7.4.5.5.1 Market size and forecast, by Type 7.4.5.5.2 Market size and forecast, by Therapy 7.4.5.5.3 Market size and forecast, by Distribution Channel 7.4.5.6 Rest of Asia-Pacific 7.4.5.6.1 Market size and forecast, by Type 7.4.5.6.2 Market size and forecast, by Therapy 7.4.5.6.3 Market size and forecast, by Distribution Channel 7.5 LAMEA 7.5.1 Key trends and opportunities 7.5.2 LAMEA Market size and forecast, by Type 7.5.3 LAMEA Market size and forecast, by Therapy 7.5.4 LAMEA Market size and forecast, by Distribution Channel 7.5.5 LAMEA Market size and forecast, by country 7.5.5.1 Brazil 7.5.5.1.1 Market size and forecast, by Type 7.5.5.1.2 Market size and forecast, by Therapy 7.5.5.1.3 Market size and forecast, by Distribution Channel 7.5.5.2 Saudi Arabia 7.5.5.2.1 Market size and forecast, by Type 7.5.5.2.2 Market size and forecast, by Therapy 7.5.5.2.3 Market size and forecast, by Distribution Channel 7.5.5.3 South Africa 7.5.5.3.1 Market size and forecast, by Type 7.5.5.3.2 Market size and forecast, by Therapy 7.5.5.3.3 Market size and forecast, by Distribution Channel 7.5.5.4 Rest of LAMEA 7.5.5.4.1 Market size and forecast, by Type 7.5.5.4.2 Market size and forecast, by Therapy 7.5.5.4.3 Market size and forecast, by Distribution Channel CHAPTER 8: COMPANY LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Key developments CHAPTER 9: COMPANY PROFILES 9.1 Abbott Laboratories 9.1.1 Company overview 9.1.2 Company snapshot 9.1.3 Operating business segments 9.1.4 Product portfolio 9.1.5 Business performance 9.1.6 Key strategic moves and developments 9.2 Alnylam Pharmaceuticals, Inc. 9.2.1 Company overview 9.2.2 Company snapshot 9.2.3 Operating business segments 9.2.4 Product portfolio 9.2.5 Business performance 9.2.6 Key strategic moves and developments 9.3 Biogen idc 9.3.1 Company overview 9.3.2 Company snapshot 9.3.3 Operating business segments 9.3.4 Product portfolio 9.3.5 Business performance 9.3.6 Key strategic moves and developments 9.4 Bluebird, Inc. 9.4.1 Company overview 9.4.2 Company snapshot 9.4.3 Operating business segments 9.4.4 Product portfolio 9.4.5 Business performance 9.4.6 Key strategic moves and developments 9.5 Bristol Myers Squibb 9.5.1 Company overview 9.5.2 Company snapshot 9.5.3 Operating business segments 9.5.4 Product portfolio 9.5.5 Business performance 9.5.6 Key strategic moves and developments 9.6 Danaher Corporation 9.6.1 Company overview 9.6.2 Company snapshot 9.6.3 Operating business segments 9.6.4 Product portfolio 9.6.5 Business performance 9.6.6 Key strategic moves and developments 9.7 Emmaus Life Sciences, Inc. 9.7.1 Company overview 9.7.2 Company snapshot 9.7.3 Operating business segments 9.7.4 Product portfolio 9.7.5 Business performance 9.7.6 Key strategic moves and developments 9.8 Global Blood Therapeutics, Inc. 9.8.1 Company overview 9.8.2 Company snapshot 9.8.3 Operating business segments 9.8.4 Product portfolio 9.8.5 Business performance 9.8.6 Key strategic moves and developments 9.9 Merck & Co. Inc. 9.9.1 Company overview 9.9.2 Company snapshot 9.9.3 Operating business segments 9.9.4 Product portfolio 9.9.5 Business performance 9.9.6 Key strategic moves and developments 9.10 Novartis AG 9.10.1 Company overview 9.10.2 Company snapshot 9.10.3 Operating business segments 9.10.4 Product portfolio 9.10.5 Business performance 9.10.6 Key strategic moves and developments 9.11 Pfizer 9.11.1 Company overview 9.11.2 Company snapshot 9.11.3 Operating business segments 9.11.4 Product portfolio 9.11.5 Business performance 9.11.6 Key strategic moves and developments 9.12 Prolong Pharmaceuticals 9.12.1 Company overview 9.12.2 Company snapshot 9.12.3 Operating business segments 9.12.4 Product portfolio 9.12.5 Business performance 9.12.6 Key strategic moves and developments 9.13 Sangamo Therapeutics, Inc. 9.13.1 Company overview 9.13.2 Company snapshot 9.13.3 Operating business segments 9.13.4 Product portfolio 9.13.5 Business performance 9.13.6 Key strategic moves and developments 9.14 Sanofi 9.14.1 Company overview 9.14.2 Company snapshot 9.14.3 Operating business segments 9.14.4 Product portfolio 9.14.5 Business performance 9.14.6 Key strategic moves and developments 9.15 Cancer Therapeutics CRC Pty Ltd 9.15.1 Company overview 9.15.2 Company snapshot 9.15.3 Operating business segments 9.15.4 Product portfolio 9.15.5 Business performance 9.15.6 Key strategic moves and developments 9.16 Gamida-Cell Ltd. 9.16.1 Company overview 9.16.2 Company snapshot 9.16.3 Operating business segments 9.16.4 Product portfolio 9.16.5 Business performance 9.16.6 Key strategic moves and developments
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（通信回線）の最新刊レポート
Allied Market Research 社の最新刊レポート
本レポートと同じKEY WORD（distribution channel）の最新刊レポート
よくあるご質問Allied Market Research社はどのような調査会社ですか?アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/07/03 10:27 162.61 円 175.23 円 209.12 円 |
